Rare NSCLC Subtypes & Targeted Therapy: Learning Curves
- A leading oncologist discusses the challenges of biomarker-driven therapy, real-world evidence, and equitable access to testing in NSCLC care.
- Non-small cell lung cancer (NSCLC) treatment has undergone a dramatic transformation, evolving from a relatively uniform approach to a highly individualized one based on biomarker testing.
- Specialists, like himself, who focus exclusively on lung cancer, are readily familiar with the nuances of various subtypes and their corresponding therapies.
“`html
Table of Contents
A leading oncologist discusses the challenges of biomarker-driven therapy, real-world evidence, and equitable access to testing in NSCLC care.
The Growing Complexity of NSCLC
Non-small cell lung cancer (NSCLC) treatment has undergone a dramatic transformation, evolving from a relatively uniform approach to a highly individualized one based on biomarker testing. Though, this progress introduces significant challenges for oncologists, particularly those in community settings who may encounter rare molecular subtypes infrequently. Jorge Nieva, MD, of the Keck School of medicine of the University of Southern California, recently addressed these issues at an Institute for Value-Based Medicine® event.
The Volume Problem: Specialist vs. Community Oncologist
Dr. Nieva highlighted a critical disparity in expertise. Specialists, like himself, who focus exclusively on lung cancer, are readily familiar with the nuances of various subtypes and their corresponding therapies. Though, general oncologists, particularly those practicing in regions with high smoking rates, may encounter these rarer, non-smoking-related NSCLC subtypes less frequently enough. This limited exposure can make it difficult to confidently translate biomarker results into optimal treatment decisions.
Consider the prevalence of different NSCLC subtypes. According to the National Cancer Institute, approximately 80-85% of NSCLC cases are adenocarcinoma, while other subtypes like squamous cell carcinoma, large cell carcinoma, and adenosquamous carcinoma account for the remaining 15-20%. Within adenocarcinoma, specific driver mutations like EGFR, ALK, and ROS1 are present in varying percentages, further complicating treatment selection. A community oncologist seeing primarily adenocarcinoma may still rarely encounter patients with ALK or ROS1 rearrangements, requiring them to quickly become proficient in therapies they may only use a few times in their career.
The Importance of Repeat Biomarker Testing
Dr. nieva emphasized that biomarker testing isn’t a one-time event. The advancement of resistance mutations is a common challenge in NSCLC treatment. Repeat testing allows clinicians to identify these mutations and adjust treatment strategies accordingly.This is particularly crucial as targeted therapies become more prevalent and resistance mechanisms emerge.
For example, patients initially responding to EGFR tyrosine kinase inhibitors (TKIs) ofen develop the T790M resistance mutation. identifying this mutation allows for a switch to osimertinib, a third-generation EGFR TKI specifically designed to overcome this resistance. Similarly, resistance to ALK inhibitors can arise through various mechanisms, necessitating repeat testing to guide subsequent treatment choices.
Real-World Evidence and Beyond Clinical Trials
While clinical trials provide crucial data on the efficacy of new therapies, they don’t always reflect the complexities of real-world patient populations. Dr. Nieva underscored the importance of leveraging real-world evidence (RWE) to inform treatment decisions outside the clinical trial setting. RWE, derived from electronic health records, claims data, and patient registries, can provide valuable insights into treatment patterns, outcomes, and safety in diverse patient groups.